Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with anastrozole.
Tamoxifen was granted FDA approval on 30 December 1977.
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Primary Peritoneal Cavity CancerStage III Ovarian Epithelial CancerRecurrent Ovarian Epithelial CancerFallopian Tube CancerStage IV Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 139
- Registration Number
- NCT00041080
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
- Conditions
- Neoplasm MetastasisOsteosarcoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00001436
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4740
- Registration Number
- NCT00038467
- Locations
- 🇬🇧
Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
- Conditions
- Breast Neoplasms
- First Posted Date
- 2002-04-24
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034125
Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2001-11-12
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 50
- Registration Number
- NCT00026585
- Locations
- 🇺🇸
Howard University Hospital, Washington, D.C., District of Columbia, United States
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
- Conditions
- Breast CancerBreast Neoplasm
- Interventions
- First Posted Date
- 2000-06-14
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00005908
- Locations
- 🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States
Tamoxifen Study
- Conditions
- Cardiovascular DiseasesCoronary DiseaseHeart DiseasesHypertensionMyocardial Ischemia
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT00000529
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.